23andMe Holding Co.
NASDAQ:ME

Watchlist Manager
23andMe Holding Co. Logo
23andMe Holding Co.
NASDAQ:ME
Watchlist
Price: 0.6063 USD -21.26% Market Closed
Market Cap: 88.5m USD

ME's latest stock split occurred on Oct 16, 2024

The company executed a 1-for-20 stock split, meaning that for every 20 shares held, investors received 1 new share.

Before the split, ME traded at 0.2701 per share. Afterward, the share price was about 5.34.

The adjusted shares began trading on Oct 16, 2024. This was the only stock split in ME's history.

Last Splits:
Oct 16, 2024
1-for-20
Pre-Split Price
5.402 0.2701
Post-Split Price
5.34
Before
After
Last Splits:
Oct 16, 2024
1-for-20

23andMe Holding Co.
Stock Splits History

ME Stock Splits Timeline
Oct 16, 2024
Oct 16, 2024
Split 1-for-20
/0.05
Pre-Split Price
5.402 0.2701
Post-Split Price
5.34
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.13 0.13 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.41 8.41 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Dec 30, 2025
Adicet Bio Inc
NASDAQ:ACET
1-for-16
/16
0.4921 0.4921 USD 7.93 7.93 USD
Load More

23andMe Holding Co.
Glance View

Market Cap
88.5m USD
Industry
Health Care

23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. The company is headquartered in South San Francisco, California. The company went IPO on 2020-10-06. The firm offers direct-to-consumer genetic testing and personalized information about genetic health risks, ancestry, and traits. The firm operates through two segments: Consumer & Research Services and Therapeutics. Its consumer & research services business segment comprises personal genome service (PGS) and research services. Its PGS provides a suite of genetic reports, including information on genetic ancestral origins, personal genetic health risks, rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Company’s therapeutics segment focuses on drug development for discovering and developing therapies to improve patient lives and includes out-licensing of intellectual property. The Company’s programs across therapeutic areas, include oncology, immunology, neurology, metabolic and cardiovascular diseases.

ME Intrinsic Value
Not Available
Back to Top